TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00816790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Description: Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
Study: NCT03280147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-day course of antibiotics
Description: Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day course of antibiotics
Description: Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned.
Study: NCT00604825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK232802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREMARIN
Study: NCT00722280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand Transplantation
Description: This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants.
Study: NCT00145769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Adjuvent Chemotherapy
Description: Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Course Adjuvant Chemotherapy
Description: Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Radiotherapy
Description: 25 Gy in 5 fractions over 5 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long Course Radiotherapy
Description: 50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: 5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial Surgery
Description: Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
Study: NCT04458675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A biodegradable capsule, which visually similar to the Vibrant active capsule
Study: NCT02509377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Fetal Repair of Myelomeningocele
Description: Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
Study: NCT06718712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body resistance training
Description: The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body resistance training
Description: The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.
Study: NCT00103285

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT04500769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
Study: NCT00103285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02070679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Study: NCT03349619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol plus Carboxymethyl-β-Glucan
Description: Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
Study: NCT01615289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 250 ml green tea extract
Description: Intragastric instillation by feeding tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 500 ml green tea extract
Description: Intragastric instillation by feeding tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 250 ml control solution
Description: Intragastric instillation by feeding tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 500 ml control solution
Description: Intragastric instillation by feeding tube
Study: NCT01764893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTNS plus solifenacin
Description: 12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
Study: NCT04115657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 1
Description: Consumption of milk tea with sucrose and boba pearls made from tapioca starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 2
Description: Consumption of milk tea with sucrose and boba pearls made from high amylose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 3
Description: Consumption of milk tea with sucrose and boba pearls made from kithul flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch 4
Description: Consumption of milk tea with sucrose and boba pearls made from sago flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar 1
Description: Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar 2
Description: Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
Study: NCT00159263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Inhalant Powder
Description: 12ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Powder
Description: Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Powder
Description: Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and Formoterol Product
Description: Combination Inhaler, Symbicort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and Formoterol Product
Description: Combination Inhaler, Symbicort
Study: NCT04018274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 mg by mouth (PO) once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 mg by mouth (PO) once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel(LN)
Description: Oral tablet containing 30 ug EE and 150 ug of LN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel(LN)
Description: Oral tablet containing 30 ug EE and 150 ug of LN
Study: NCT04093089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionode IOP Lowering System
Description: Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bionode IOP Lowering System
Description: Control: No stimulation
Study: NCT01038375

Intervention type: BEHAVIORAL
Intervention: lifestyle counseling, home blood pressure monitoring
Description: monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group

Intervention type: BEHAVIORAL
Intervention: lifestyle counseling, home blood pressure monitoring
Description: monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
Study: NCT04292704

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: the fractional CO2 laser
Description: The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m

Intervention type: DRUG
Group type: OTHER
Intervention: Clotrimazole
Description: Clotrimazole vaginal tablets
Study: NCT04103567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
Study: NCT00103285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03081247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF 320/14.4/9.6 µg MDI
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF 320/9.6 µg
Description: Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
Study: NCT03722706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handbook
Description: The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
Study: NCT03551847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: The intervention involves giving an infected patient antibiotics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antibiotics
Description: The intervention involves not giving an infected patient antibiotics.
Study: NCT04470973

Intervention type: DRUG
Intervention: Cefuroxime
Description: Patients receive cefuroxime as part of standard care.

Intervention type: DRUG
Intervention: Amikacin
Description: Patients receive amikacin as part of standard care.
Study: NCT05329857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin 1000/50 mg
Description: 50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin 1000/50 mg
Description: 50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
Study: NCT02970955

Intervention type: PROCEDURE
Intervention: Inoperable thoracic nodes metastases
Description: The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
Study: NCT02672098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C).
Study: NCT03804268

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
Study: NCT03906812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry
Description: Bed type assignment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unmonitored
Description: Bed type assignment
Study: NCT03037515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
Study: NCT02461537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAM
Description: High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC and/or Mitoxantrone
Description: Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
Study: NCT03898622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
Study: NCT04838002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Focus and Radial types Extracorporeal shock wave therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Focus and Radial types Extracorporeal shock wave therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Focus and Radial types Extracorporeal shock wave therapy
Study: NCT03498521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Subcutaneous (SC)
Description: Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Study: NCT03440957

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic treatment
Description: The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
Study: NCT02613377

Intervention type: OTHER
Intervention: Blood transfusion
Study: NCT03668639

Intervention type: DRUG
Group type: OTHER
Intervention: Akynzeo
Description: Weekly administration of akynzeo for five weeks.
Study: NCT03365661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains \> 2 x 105 α/β T cells/kg recipient weight.